Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Interest Expenses for 7 consecutive years, with $90000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 52.54% to $90000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368000.0 through Dec 2025, up 47.79% year-over-year, with the annual reading at $370000.0 for FY2025, 48.59% up from the prior year.
  • Interest Expenses for Q4 2025 was $90000.0 at Kymera Therapeutics, down from $98000.0 in the prior quarter.
  • The five-year high for Interest Expenses was $108000.0 in Q2 2025, with the low at $24000.0 in Q1 2021.
  • Average Interest Expenses over 5 years is $58150.0, with a median of $57000.0 recorded in 2022.
  • The sharpest move saw Interest Expenses soared 150.0% in 2021, then tumbled 48.57% in 2022.
  • Over 5 years, Interest Expenses stood at $51000.0 in 2021, then grew by 15.69% to $59000.0 in 2022, then fell by 11.86% to $52000.0 in 2023, then rose by 13.46% to $59000.0 in 2024, then skyrocketed by 52.54% to $90000.0 in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $90000.0, $98000.0, and $108000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.